Altered GABAergic Signaling in Brain Disease at Various Stages of Life

다국어 초록 (Multilingual Abstract)

In the healthy brain, gamma-aminobutyric acid (GABA) is regulated by neurons and glia. This begs the question: what happens in the malfunctioning brain? There are many reasons why diseases occur, including genetic mutations, systemic problems, and environmental influences. There are also many ways in which GABA can become dysregulated, such as through alterations in its synthesis or release, and changes in systems that respond to it. Notably, dysregulation of GABA can have a large impact on the brain. To date, few reviews have examined brain diseases in which dysregulation of GABA is implicated as an underlying factor. Accordingly, the time is ripe for investigating alterations in GABAergic signaling that may play a role in changes in neuronal activity observed in the major brain disorders that occur during various stages of life. This review is meant to provide a better understanding of the role of GABA in brain health and contributor to social problems from a scientific perspective.

참고문헌 (Reference)

1 Grillner S, "Worldwide initiatives to advance brain research" 19 : 1118-1122, 2016

2 Farrant M, "Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors" 6 : 215-229, 2005

3 Wu Z, "Tonic inhibition in dentate gyrus impairs long-term potentiation and memory in an Alzheimer’s [corrected] disease model" 5 : 4159-, 2014

4 Shakirullah, "The prevalence, incidence and etiology of epilepsy" 2 : 29-39, 2014

5 Garbutt JC, "The interaction between GABA and dopamine: implications for schizophrenia" 9 : 336-353, 1983

6 Amunts K, "The human brain project: creating a European research infrastructure to decode the human brain" 92 : 574-581, 2016

7 World Health Organization, "The global burden of disease:2004 update" World Health Organization 2008

8 Gross C, "The developmental origins of anxiety" 5 : 545-552, 2004

9 Kessler RC, "The costs of depression" 35 : 1-14, 2012

10 DiLuca M, "The cost of brain diseases: a burden or a challenge?" 82 : 1205-1208, 2014

11 De Strooper B, "The cellular phase of Alzheimer’s disease" 164 : 603-615, 2016

12 Olesen J, "The burden of brain diseases in Europe" 10 : 471-477, 2003

13 Luscher B, "The GABAergic deficit hypothesis of major depressive disorder" 16 : 383-406, 2011

14 Braat S, "The GABAA receptor as a therapeutic target for neurodevelopmental disorders" 86 : 1119-1130, 2015

15 Möhler H, "The GABA system in anxiety and depression and its therapeutic potential" 62 : 42-53, 2012

16 Heaney CF, "Role of GABA(B) receptors in learning and memory and neurological disorders" 63 : 1-28, 2016

17 Kalueff A, "Role of GABA in memory and anxiety" 4 : 100-110, 1996

18 Kalueff AV, "Role of GABA in anxiety and depression" 24 : 495-517, 2007

19 Substance Abuse and Mental Health Services Administration (US), "Results from the 2008 national survey on drug use and health: national findings" Substance Abuse and Mental Health Services Administration 2009

20 Stell BM, "Receptors with different affinities mediate phasic and tonic GABA(A) conductances in hippocampal neurons" 22 : RC223-, 2002

21 Getahun D, "Recent trends in childhood attentiondeficit/hyperactivity disorder" 167 : 282-288, 2013

22 Autism and Developmental Disabilities Monitoring Network Surveillance Year 2008 Principal Investigators, "Prevalence of autism spectrum disorders--Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008" 61 : 1-19, 2012

23 Christensen DL, "Prevalence and characteristics of autism spectrum disorder among children aged 8 years--autism and developmental disabilities monitoring network, 11 sites, United States, 2012" 65 : 1-23, 2016

24 Tao W, "Postsynaptic GABAB receptors enhance extrasynaptic GABAA receptor function in dentate gyrus granule cells" 33 : 3738-3743, 2013

25 Wu Y, "Nonvesicular inhibitory neurotransmission via reversal of the GABA transporter GAT-1" 56 : 851-865, 2007

26 Carver CM, "Neurosteroid interactions with synaptic and extrasynaptic GABA(A) receptors: regulation of subunit plasticity, phasic and tonic inhibition, and neuronal network excitability" 230 : 151-188, 2013

27 Luchetti S, "Neurosteroid and GABA-A receptor alterations in Alzheimer’s disease, Parkinson’s disease and multiple sclerosis" 191 : 6-21, 2011

28 Davis KL, "Neuropsychopharmacology:the fifth generation of progress" Lippincott Williams & Wilkins 2002

29 World Health Organization, "Neurological disorders:public health challenges" World Health Organization 2006

30 Yizhar O, "Neocortical excitation/inhibition balance in information processing and social dysfunction" 477 : 171-178, 2011

31 Perou R, "Mental health surveillance among children--United States, 2005-2011" 62 : 1-35, 2013

32 Tritsch NX, "Mechanisms and functions of GABA co-release" 17 : 139-145, 2016

33 Sterley TL, "Maternal separation increases GABA(A) receptor-mediated modulation of norepinephrine release in the hippocampus of a rat model of ADHD, the spontaneously hypertensive rat" 1497 : 23-31, 2013

34 Kessler RC, "Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication" 62 : 593-602, 2005

35 Jeong SJ, "Korea brain initiative: integration and control of brain functions" 92 : 607-611, 2016

36 Salpekar JA, "Key issues in addressing the comorbidity of attention deficit hyperactivity disorder and pediatric epilepsy" 37 : 310-315, 2014

37 Trousselard M, "Is plasma GABA level a biomarker of post-traumatic stress disorder (PTSD) severity? A preliminary study" 241 : 273-279, 2016

38 Yuan H, "Ionotropic GABA and glutamate receptor mutations and human neurologic diseases" 88 : 203-217, 2015

39 Wang T, "Involvement of lateral habenula α1 subunit-containing GABAA receptor-mediated inhibitory transmission in the regulation of depression-related behaviors in experimental Parkinson’s disease" 116 : 399-411, 2017

40 Maletic V, "Integrated neurobiology of bipolar disorder" 5 : 98-, 2014

41 Curtin SC, "Increase in suicide in the United States, 1999-2014" 1-8, 2014

42 Li Y, "Implications of GABAergic neurotransmission in Alzheimer’s disease" 8 : 31-, 2016

43 Naaijen J, "Glutamatergic and GABAergic gene sets in attention-deficit/hyperactivity disorder:association to overlapping traits in ADHD and autism" 7 : e999-, 2017

44 Zhou Y, "Glutamate as a neurotransmitter in the healthy brain" 121 : 799-817, 2014

45 McGeer PL, "Glial reactions in Parkinson’s disease" 23 : 474-483, 2008

46 Pandolfo M, "Genetics of epilepsy" 31 : 506-518, 2011

47 Sharp SI, "Genetics of attention-deficit hyperactivity disorder (ADHD)" 57 : 590-600, 2009

48 El-Ansary A, "GABAergic/glutamatergic imbalance relative to excessive neuroinflammation in autism spectrum disorders" 11 : 189-, 2014

49 Couve A, "GABAB receptors:a new paradigm in G protein signaling" 16 : 296-312, 2000

50 Shetty AK, "GABA-ergic cell therapy for epilepsy: advances, limitations and challenges" 62 : 35-47, 2016

51 Unichenko P, "GABA transporters control GABAergic neurotransmission in the mouse subplate" 304 : 217-227, 2015

52 Yu Z, "GABA transporter-1 deficiency confers schizophrenia-like behavioral phenotypes" 8 : e69883-, 2013

53 Giachino C, "GABA suppresses neurogenesis in the adult hippocampus through GABAB receptors" 141 : 83-90, 2014

54 Fatemi SH, "GABA receptor subunit distribution and FMRP-mGluR5 signaling abnormalities in the cerebellum of subjects with schizophrenia, mood disorders, and autism" 167 : 42-56, 2015

55 Jo S, "GABA from reactive astrocytes impairs memory in mouse models of Alzheimer’s disease" 20 : 886-896, 2014

56 Kaila K, "GABA actions and ionic plasticity in epilepsy" 26 : 34-41, 2014

57 Gilman SE, "Family disruption in childhood and risk of adult depression" 160 : 939-946, 2003

58 Lee E, "Excitation/inhibition imbalance in animal models of autism spectrum disorders" 81 : 838-847, 2017

59 Sterley TL, "Evidence for reduced tonic levels of GABA in the hippocampus of an animal model of ADHD, the spontaneously hypertensive rat" 1541 : 52-60, 2013

60 Carney P, "Epilepsy syndromes in children" 34 : 1009-1015, 2005

61 Featherstone V, "Epilepsy in children and young people" Cerebra 2010

62 Jokiranta E, "Epilepsy among children and adolescents with autism spectrum disorders: a populationbased study" 44 : 2547-2557, 2014

63 Rugg-Gunn FJ, "Epilepsy 2015 from channels to commissioning: a practical guide to epilepsy" Interna tional League Against Epilepsy 149-156, 2011

64 de Lau LM, "Epidemiology of Parkinson’s disease" 5 : 525-535, 2006

65 Cope DW, "Enhanced tonic GABAA inhibition in typical absence epilepsy" 15 : 1392-1398, 2009

66 Australian Brain Alliance Steering Committee, "Electronic address:[e-mail]; Australian Brain Alliance Steering Committee (2016) Australian brain alliance" 92 : 597-600, 2016

67 Gogtay N, "Dynamic mapping of human cortical development during childhood through early adulthood" 101 : 8174-8179, 2004

68 Cryan JF, "Don’t worry ‘B’ happy!: a role for GABA(B) receptors in anxiety and depression" 26 : 36-43, 2005

69 American Psychiatric Association, "Diagnostic and statistical manual of mental disorders: DSM-5®" American Psychiatric Association 2013

70 Pratt LA, "Depression in the U.S. household population, 2009-2012" 1-8, 2014

71 Tsai LY, "DSM-5 ASD moves forward into the past" 44 : 321-330, 2014

72 Comings DE, "Clinical and molecular genetics of ADHD and Tourette syndrome. Two related polygenic disorders" 931 : 50-83, 2001

73 Poo MM, "China brain project: basic neuroscience, brain diseases, and braininspired computing" 92 : 591-596, 2016

74 Okano H, "Brain/MINDS: a Japanese national brain project for marmoset neuroscience" 92 : 582-590, 2016

75 Supekar K, "Brain hyperconnectivity in children with autism and its links to social deficits" 5 : 738-747, 2013

76 Jabalpurwala I, "Brain Canada: one brain one community" 92 : 601-606, 2016

77 Osborn LM, "Astrogliosis:an integral player in the pathogenesis of Alzheimer’s disease" 144 : 121-141, 2016

78 Schousboe A, "Astrocytic control of biosynthesis and turnover of the neurotransmitters glutamate and GABA" 4 : 102-, 2013

79 Duncan NW, "Associations of regional GABA and glutamate with intrinsic and extrinsic neural activity in humans—a review of multimodal imaging studies" 47 : 36-52, 2014

80 Pastor P, "Association between diagnosed ADHD and selected characteristics among children aged 4-17 years: United States, 2011-2013" 201 : 2013

81 Pizzarelli R, "Alterations of GABAergic signaling in autism spectrum disorders" 2011 : 297153-, 2011

82 Hanchar HJ, "Alcohol-induced motor impairment caused by increased extrasynaptic GABA(A) receptor activity" 8 : 339-345, 2005

83 Niccoli T, "Ageing as a risk factor for disease" 22 : R741-R752, 2012

84 Biederman J, "Age-dependent decline of symptoms of attention deficit hyperactivity disorder:impact of remission definition and symptom type" 157 : 816-818, 2000

85 Brichta L, "Advances in the pharmacological treatment of Parkinson’s disease: targeting neurotransmitter systems" 36 : 543-554, 2013

86 Sahay A, "Adult hippocampal neurogenesis in depression" 10 : 1110-1115, 2007

87 Kersanté F, "A functional role for both -aminobutyric acid (GABA) transporter-1 and GABA transporter-3 in the modulation of extracellular GABA and GABAergic tonic conductances in the rat hippocampus" 591 : 2429-2441, 2013

88 Masten AS, "A developmental perspective on underage alcohol use" 32 : 3-15, 2009

89 Lam PM, "A calpain inhibitor ameliorates seizure burden in an experimental model of temporal lobe epilepsy" 102 : 1-10, 2017

90 Alzheimer’s Association, "2016 Alzheimer’s disease facts and figures" 12 : 459-509, 2016